Local Coverage Article: Investigational Device Exemptions (IDE) - IDE Documentation Requirements for Studies with an FDA Approval dated January 01, 2015 or later (A54919)

Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website.

Contractor Information

<table>
<thead>
<tr>
<th>Contractor Name</th>
<th>Contract Type</th>
<th>Contract Number</th>
<th>Jurisdiction</th>
<th>State(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Noridian Healthcare Solutions, LLC</td>
<td>A and B MAC</td>
<td>01111 - MAC A</td>
<td>J - E</td>
<td>California - Entire State</td>
</tr>
<tr>
<td>Noridian Healthcare Solutions, LLC</td>
<td>A and B MAC</td>
<td>01112 - MAC B</td>
<td>J - E</td>
<td>California - Northern</td>
</tr>
<tr>
<td>Noridian Healthcare Solutions, LLC</td>
<td>A and B MAC</td>
<td>01182 - MAC B</td>
<td>J - E</td>
<td>California - Southern American Samoa Guam Hawaii Northern Mariana Islands American Samoa Guam Hawaii Northern Mariana Islands Nevada Nevada Nevada American Samoa California - Entire State Guam Hawaii Nevada Northern Mariana Islands</td>
</tr>
<tr>
<td>Noridian Healthcare Solutions, LLC</td>
<td>A and B MAC</td>
<td>01211 - MAC A</td>
<td>J - E</td>
<td></td>
</tr>
<tr>
<td>Noridian Healthcare Solutions, LLC</td>
<td>A and B MAC</td>
<td>01212 - MAC B</td>
<td>J - E</td>
<td></td>
</tr>
<tr>
<td>Noridian Healthcare Solutions, LLC</td>
<td>A and B MAC</td>
<td>01311 - MAC A</td>
<td>J - E</td>
<td>Nevada American Samoa California - Entire State Guam Hawaii Nevada Northern Mariana Islands American Samoa Guam Hawaii Northern Mariana Islands</td>
</tr>
<tr>
<td>Noridian Healthcare Solutions, LLC</td>
<td>A and B MAC</td>
<td>01312 - MAC B</td>
<td>J - E</td>
<td></td>
</tr>
<tr>
<td>Noridian Healthcare Solutions, LLC</td>
<td>A and B MAC</td>
<td>01911 - MAC A</td>
<td>J - E</td>
<td></td>
</tr>
</tbody>
</table>

Back to Top

Article Information

General Information

<table>
<thead>
<tr>
<th>Article ID</th>
<th>A54919</th>
</tr>
</thead>
<tbody>
<tr>
<td>Article Title</td>
<td>Investigational Device Exemptions (IDE) - IDE Documentation Requirements for Studies with an FDA Approval dated January 01, 2015 or later</td>
</tr>
<tr>
<td>AMA CPT / ADA CDT / AHA NUBC Copyright Statement</td>
<td></td>
</tr>
</tbody>
</table>

Original Article Effective Date
10/01/2015

Revision Effective Date
10/01/2015

Revision Ending Date
N/A

Retirement Date
N/A
Article Guidance

Article Text:

Effective January 01, 2015, CMS Coverage Analysis Group began reviewing all IDE trials for approval. Once CMS approves the trial they list the trial on their web site as approved. This process is streamlining the approval process for all parties involved.

Noridian has reviewed our requirements for such studies. For IDE trials with an FDA approval letter on or after January 01, 2015 that have been approved by CMS Noridian will only require:

1. Notice of participation in the trial,
2. IDE designator assigned by the FDA
3. Clinical trial number as listed on clinical trials.gov

A letter including the three above stated requirements along with the PTAN of the facility, the names of the principal investigator, study doctors and their NPIs is to be submitted at time of request to Noridian.

Such notice is necessary to input into the Noridian claims payment systems to assure proper processing of our provider’s claims related to such trial. For further information on this process please visit the CMS website: CMS website

IDE Documentation Requirements for Studies with an FDA Approval dated prior to January 01, 2015

For any IDE trial with an FDA approval letter date before January 01, 2015, Noridian will continue to require the following documentation:

1. Name of the trial, the assigned FDA IDE number and the Clinical Trial number;
2. The study protocol;
3. The most recent institutional IRB approval letter;
4. The most recent IRB approved informed consent which includes a financial disclosure for the facility and investigators;
5. For the purposes of an IDE approval the following financial disclosures shall be included in the informed consent and be clearly marked as such therein:
• Funding source(s) for the project;

• Funding for the facility;

• Funding for the investigators and if that funding is direct to the provider or if the facility is provided funds to offset his/her salary

• Any relationship that the provider has with the sponsor. These include but are not limited to being a speaker for the sponsor, receiving other gratuities from the sponsor and/or being a paid consultant for the sponsor.

• Other financial interests in the sponsor(s) such as stocks or other investments;

• Any other potential conflict of interest as it regards the respective study;

• Any such interest as disclosed to the Institutional Review Board.

The informed consent does not necessarily need to include the extent of such potential conflict (e.g. how many stocks the institution/primary investigator (PI)/secondary or other investigators (SI) has from the sponsor or the actual monies paid directly to the institution/PI/SI) only that one exits. Noridian does reserve the right to request a budgetary review of IDE trials/studies but the latter does not need to be submitted with the application.

Failure to provide such information either in the affirmative with a listing of such items or in the negative (no known conflicts) will result in a denial of the request. The provision of fraudulent information will be referred to Medicare enforcement agencies.

Form
FDA Approved IDE pre-Approval Data Submission Request

IDE Submissions
All IDE submissions regardless of FDA letter date should be sent to one of the following:

Email: iderequests@noridian.com
Hard Copy:
ATTN: IDE Coordinator
PO Box 6782
900 42nd St. S
Fargo, ND 58103-6722

For those IDE studies with an FDA approval letter dated before January 01, 2015, provider notification will be sent out upon approval/disapproval. If an application is approved, the system will be set to accept a provider’s claims.

For those studies with an FDA approval letter dated on or after January 01, 2015, a notice of receipt of the information and confirmation that the study has been vetted by CMS will be sent to the provider.

Resources
Providers should adhere to the CMS billing requirements to ensure the proper processing of IDE claims.

CMS Internet Only Manual (IOM), Publication 100-4, Medicare Claims Processing Manual, Chapter 32, Section 68
IOM, Publication 100-02, Medicare Benefit Policy Manual, Chapter 14, Section 20
Federal Register Vol. 78, No. 237
CMS Change REQuest (CR) 8401

Coding Information
Printed on 3/1/2018. Page 3 of 5
Bill Type Codes:

Contractors may specify Bill Types to help providers identify those Bill Types typically used to report this service. Absence of a Bill Type does not guarantee that the article does not apply to that Bill Type. Complete absence of all Bill Types indicates that coverage is not influenced by Bill Type and the article should be assumed to apply equally to all claims.

N/A

Revenue Codes:

Contractors may specify Revenue Codes to help providers identify those Revenue Codes typically used to report this service. In most instances Revenue Codes are purely advisory. Unless specified in the article, services reported under other Revenue Codes are equally subject to this coverage determination. Complete absence of all Revenue Codes indicates that coverage is not influenced by Revenue Code and the article should be assumed to apply equally to all Revenue Codes.

N/A

CPT/HCPCS Codes N/A

ICD-10 Codes that are Covered N/A

ICD-10 Codes that are Not Covered N/A

Related Local Coverage Document(s) N/A

Related National Coverage Document(s) N/A

Statutory Requirements URL(s) N/A

Rules and Regulations URL(s) N/A


Other URL(s) MLN Matters Article

Public Version(s) Updated on 03/15/2016 with effective dates 10/01/2015 - N/A Updated on 03/10/2016 with effective dates 10/01/2015 - N/A Updated on 02/18/2016 with effective dates 10/01/2015 - N/A Back to Top

Keywords
• Investigational Device Exception
• IDE
• Clinical trial

Read the Article Disclaimer Back to Top